With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans

With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing. For example, on Tuesday, Swiss pharma giant Roche announced plans to offer its treatment for spinal muscular atrophy, should it be approved by the U.S. Food and Drug Administration (FDA), at a lower price-point than the other two options on the market. Roche’s pricing plans would make up for it being third-to-market, behind Biogen and Novartis. Roche anticipates the FDA to make a decision on its treatment, risdiplam, in May.